Grzegorz Sochań

Grzegorz Sochań

Auto-generated profile, based on publicly available information

Grzegorz Sochań

Jagiellonian University Medical College , Kraków , Poland

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2026 in Biuletyn Głównej Biblioteki Lekarskiej
Verified
Journal Article
Open access
GSGrzegorz Sochań
Grzegorz Sochań
JDJakub Tomasz Dudek
Jakub Tomasz Dudek
WGWiktoria Górecka
Wiktoria Górecka
MGMichał Górecki
Michał Górecki
KFKinga Filip
Kinga Filip
AKAleksandra Komoń
Aleksandra Komoń
Attention-Deficit/Hyperactivity Disorder (ADHD) is a prevalent neurodevelopmental disorder traditionally linked to monoaminergic dysregulation within the brain’s reward circuitry. Recent evidence points to the potential role of the gut-brain axis (GBA), a bidirectional communication network linking the central nervous system with the enteric microbiota. This narrative review explores the proposed associations between intestinal dysbiosis and ADHD symptoms, as well as the potential for GBA-targeted therapeutic interventions. Research suggests that individuals with ADHD may exhibit distinct microbial profiles, characterized by an increased abundance of genera such as Bifidobacterium and Bacteroides , and a depletion of anti-inflammatory taxa like Faecalibacterium . These shifts are hypothesized to contribute to “leaky gut” syndrome, potentially triggering systemic inflammation and neuroinflammation that could disrupt neural circuits responsible for executive function. Furthermore, experimental models indicate that gut microbes may modulate the availability of dopamine precursors, indirectly influencing reward processing. Preliminary clinical data suggest that “psychobiotics,” synbiotics, and targeted micronutrient supplementation (e.g., iron, zinc, and magnesium in cases of confirmed deficiencies) might serve as supportive interventions and potentially improve quality of life. While standard pharmacotherapy remains the primary treatment, GBA-focused strategies are being investigated as adjunctive therapies, offering a promising yet preliminary avenue for personalized management. Integrating these interventions may help manage common comorbidities across the lifespan, though further robust clinical trials are required.

18 September 2026 in Biuletyn Głównej Biblioteki Lekarskiej
Verified
Journal Article
Open access
PDF file
KBKinga Bodziony
Kinga Bodziony
APAnna Pszonka
Anna Pszonka
MGMichał Gajewski
Michał Gajewski
AGArtur Grobelny
Artur Grobelny
DWDominika Wodziak
Dominika Wodziak
KMKamal Morshed
Kamal Morshed
Background: The microbiota-gut-brain axis provides a biologically plausible framework for bidirectional communication between intestinal microorganisms and the central nervous system. Human studies have reported gut microbiota differences in autism spectrum disorder (ASD), attention-deficit hyperactivity disorder (ADHD), and schizophrenia, but the reproducibility and clinical meaning of these observations remain uncertain. Objective: To critically summarize human evidence on gut microbiota composition in ASD, ADHD, and schizophrenia, and to assess clinical evidence for probiotic and synbiotic formulations and fecal microbiota transplantation (FMT) in these disorders. Methods: A focused narrative review was conducted using PubMed and supplementary Google Scholar searches. Publications from 1 January 2012 to 31 December 2024 were considered, and the final search update was completed on 28 February 2025. Forty-two publications were purposively selected and synthesized; original human studies were prioritized whenever available. Evidence was interpreted with attention to study design, sample size, medication exposure, diet, gastrointestinal symptoms, stool characteristics, sequencing and bioinformatics methods, outcome selection, safety reporting, and risk of reverse causality. Because this was a narrative rather than a systematic review, no PRISMA flow diagram, duplicate independent screening, formal study-level risk-of-bias instrument, or new quantitative pooling was used. Results: Across all three disorders, individual studies and meta-analyses report group-level microbiota differences, but no reproducible disorder-specific microbial signature has been established. In ASD, dietary selectivity, gastrointestinal symptoms, and stool consistency explain an important proportion of reported associations. ADHD studies are generally small and yield conflicting diversity and taxonomic findings. In schizophrenia, associations are influenced by antipsychotic exposure, metabolic status, smoking, diet, and illness chronicity. Controlled trials and meta-analyses have not shown consistent improvement in core symptoms with probiotic or synbiotic products. Early uncontrolled microbiota-transfer studies in ASD suggested possible benefits, but a 2024 randomized placebo-controlled FMT trial did not demonstrate improvement in its primary clinical outcome. Evidence for FMT in ADHD is limited to a case report, and no controlled human efficacy evidence was identified for schizophrenia. FMT carries infectious, procedural, and uncertain long-term risks. Conclusions: Gut microbiota differences in ASD, ADHD, and schizophrenia should currently be regarded as associated features rather than established causes, diagnostic biomarkers, or validated therapeutic targets. Routine microbiome testing, probiotics or synbiotics for core symptoms, and FMT cannot be recommended as standard treatments for these disorders. Future studies require longitudinal designs, careful control of diet and medication, standardized laboratory methods, preregistered clinical outcomes, adequate power, external validation, and systematic safety monitoring.

1 June 2026 in Biuletyn Głównej Biblioteki Lekarskiej
Verified
Journal Article
Open access
JDJakub Tomasz Dudek
Jakub Tomasz Dudek
WGWiktoria Górecka
Wiktoria Górecka
ADAleksandra Dudek
Aleksandra Dudek
BGBartosz Gaweł
Bartosz Gaweł
GSGrzegorz Sochań
Grzegorz Sochań
MGMichał Górecki
Michał Górecki
Current scientific research demonstrates that cutaneous melanoma and mucosal melanoma are two distinct disease entities, considering the complexities of their diagnosis and treatment. Mucosal melanoma is characterized by a significantly poorer prognosis than cutaneous melanoma, with a 5-year overall survival (OS) rate of less than 20%. Surgical resection remains the gold standard of management; however, there is currently a paradigm shift away from routine, complication-prone completion lymph node dissection toward selective surveillance using serial ultrasound. This approach significantly improves patients’ quality of life without negatively impacting OS. Due to anatomical constraints (e.g., oral cavity, paranasal sinuses), narrow resection margins are supplemented with radiotherapy. Although this effectively reduces the risk of local recurrence, it does not prolong OS due to rapid distant metastasis, which occurs in approximately half of the patients within the first year. In systemic treatment, the standard of care involves dual immune checkpoint blockade (nivolumab plus ipilimumab) as well as BRAF/MEK and tyrosine kinase inhibitors (imatinib, nilotinib). The efficacy of immunotherapy in mucosal melanoma is significantly lower compared to that in cutaneous melanoma. The application of nivolumab plus ipilimumab yields slightly better outcomes than anti-PD-1 monotherapy; however, the proportion of patients achieving a durable response to treatment and the long-term survival rates remain highly unsatisfactory. The insufficient efficacy of current treatment paradigms highlights a critical need for the development of novel strategies. These include the broader application of Mohs micrographic surgery and the implementation of experimental therapies currently under investigation, such as anti-angiogenic treatments, oncolytic viruses, vaccines, adoptive T-cell therapies (e.g. CAR-T), bispecific antibodies (e.g. brenetafusp), and gut microbiome modulation.